Render Target: SSR
Render Timestamp: 2024-10-24T19:15:57.715Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-09-19 21:57:42.702
Product last modified at: 2024-09-19T22:12:55.259Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Dabrafenib (GSK2118436) #91942

    Product Information

    Product Usage Information

    Dabrafenib (GSK2118436) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 962 μl of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 519.6 g/mol
    Purity >98%
    Molecular Formula C23H20F3N5O2S2
    CAS 1195765-45-7
    Solubility Soluble in DMSO at 30 mg/ml or ethanol at 1 mg/ml with slight warming.

    Background

    Dabrafenib (GSK2118436) is a selective and potent B-Raf inhibitor. The compound inhibits mutant B-RafV600E and B-RafV600K with IC50 values of 0.6 nM and 0.5 nM, respectively, and is less effective at inhibiting wild-type B-Raf and C-Raf (IC50 = 3.2 nM and 5.0 nM, respectively) (1). Dabrafenib (GSK2118436) has also been shown to inhibit cell proliferation and ERK signaling in melanoma cell lines carrying the B-RafV600R and B-RafV600D mutations as compared to wild-type B-Raf (2). The specificity of this compound makes it a useful reagent when studying metastatic melanoma with B-Raf mutations (3).

    This product has applications to SARS-CoV-2 research into the mechanisms of the Novel Coronavirus, which has caused the COVID-19 pandemic.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.